Story
Sionna Therapeutics Shares Plunge 92% After Cystic Fibrosis Drug Fails Mid-Stage Trial

Sionna Therapeutics (NASDAQ: SION) shares plummeted 92% in trading on Monday after the company announced its lead drug candidate for cystic fibrosis, SION-719, failed to meet the main goal of a mid-stage clinical trial. The catastrophic stock decline reflects investor disappointment in a pivotal data readout for the company's pipeline.
Trial Fails to Meet Primary Endpoint
The company reported that its Phase 2a proof-of-concept study, called the PreciSION CF trial, did not achieve its key activity endpoint. The trial was designed to evaluate SION-719 as an add-on therapy to the current standard-of-care treatment, Trikafta.
The primary measure of success was a reduction in sweat chloride, a key biomarker for cystic fibrosis. According to Sionna, the trial showed a mean placebo-adjusted sweat chloride change of just -1.0 mmol/L, a result that was not statistically significant (p=0.7). Based on this outcome, the company stated it does not plan to advance SION-719 as an add-on treatment.
Company Cites Potential Confounders
Sionna, which received the topline data on Friday, said it is continuing to analyze the full results. The company noted that potential confounding factors were observed during the trial, including:
Ad- Higher than anticipated variability in individual sweat chloride levels.
- Differences in Trikafta exposure levels between the periods when patients received SION-719 versus a placebo.
Despite the efficacy failure, SION-719 was reported to be generally well-tolerated over the 14-day treatment period, with no serious adverse events. The company also reported that a separate Phase 1 trial for another candidate, SION-451, met its objectives, but it is now re-evaluating the next steps for that program in light of the SION-719 results.
Financial Position and Path Forward
For investors, the trial failure raises significant questions about the company's future. Sionna reported ending the second quarter with approximately $268.3 million in cash, cash equivalents, and marketable securities.
The company said it intends to take actions to preserve capital while it evaluates its next steps. Such measures often involve restructuring and halting spending on non-essential programs to extend the company's financial runway following a major clinical setback.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.